DDInter1232 DDInter1147
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries.
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Mitomycin {u} (Compound) treats {v} (Disease) stomach cancer
Mitomycin {u} (Compound) binds {v} (Gene) ABCB1
Mitomycin {u} (Compound) upregulates {v} (Gene) STAP2
Mitomycin {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Mitomycin {u} (Compound) downregulates {v} (Gene) MRPL19
Mitomycin {u} (Compound) causes {v} (Side Effect) Acute respiratory distress syndrome
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclophosphamide
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carmustine
Mitomycin (Compound) treats stomach cancer (Disease)
Mitomycin (Compound) binds ABCB1 (Gene)
Mitomycin (Compound) upregulates STAP2 (Gene)
Mitomycin (Compound) is included by Alkylating Activity (Pharmacologic Class)
Mitomycin (Compound) downregulates MRPL19 (Gene)
Mitomycin (Compound) causes Acute respiratory distress syndrome (Side Effect)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine